Dipal Doshi, President and CEO at Entrada Therapeutics, Inc. (TRDA), sold 2,092 shares at $18.01 ($38K) on 2023-04-17, disclosed to the SEC on 2023-04-19.
Scheduled sale ($38k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TRDA | SELL | 2024-05-20 | $45K | — | Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |